FUJIFILM Diosynth Biotechnologies (the Company), a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses, today announced that TG Therapeutics, Inc. (NASDAQ: TGTX) has committed to a multi-year manufacturing supply agreement for BRIUMVI® (ublitiximab-xiiy), its U.S. FDA-approved therapeutic for relapsing forms of multiple sclerosis (RMS).
Under the terms of the manufacturing supply agreement, FUJIFILM Diosynth Biotechnologies will provide secondary US-based manufacturing supply for BRIUMVI at the Company’s new biopharmaceutical manufacturing facility in Holly Springs, North Carolina, which is set to be fully operational in 2025.
“This commitment recognizes the expertise, capacity and capabilities that FUJIFILM Diosynth Biotechnologies provides with our fully integrated manufacturing network,” said Lars Petersen, president and chief executive officer, FUJIFILM Diosynth Biotechnologies. “FUJIFILM Diosynth Biotechnologies is executing an aggressive expansion strategy, providing customers access to our manufacturing network across the United States, Europe, and Japan for the purpose of meeting the growing demand for biotherapeutics and ultimately making patients’ lives better.”
Michael S. Weiss, chairman and chief executive officer of TG Therapeutics stated, “We are excited to partner with FUJIFILM Diosynth Biotechnologies as a secondary manufacturer of BRIUMVI here in the United States, and believe their expertise makes them an ideal partner for us. As we expand our commercialization efforts in MS and think about the future for BRIUMVI, we believe this is an important next step that will continue to support our growth plans and provide additional security for the supply of BRIUMVI.”
